Sunday, June 06, 2010

New AMG 386 Data Demonstrate Promising Antitumor Activity in Patients With Recurrent Ovarian Cancer

AMG 386 Treatment Response Increased With Dose And Exposure

AMG 386 Moving Into Phase 3 For Recurrent Ovarian Cancer

Separately, Two Analyses Provide Evidence Of Biomarker As Predictor Of Tumor Response To Motesanib

THOUSAND OAKS, Calif., June 6, 2010 /PRNewswire via COMTEX/ --Amgen (Nasdaq: AMGN) today announced that AMG 386, combined with paclitaxel, demonstrated antitumor activity in a randomized Phase 2 trial involving 161 patients with recurrent ovarian cancer.  The results are being presented for the first time in an oral presentation at the 2010 American Society of Clinical Oncology (ASCO) Annual Meeting. (Abstract Number: 5000)

Posted in Press Releases, Pipeline News